Laurus Labs Q2 net profit surges on 33% rise in revenue
Laurus Labs reported a net profit surge of over 100% for Q2, driven by a 33% rise in revenue. The company is implementing a transformation strategy and has operationalized its first commercial-scale peptide plant in Visakhapatnam to meet growing demand for peptide therapeutics. The firm is also acquiring a 60% stake in Galenvs Sciences Inc.